Facioscapulohumeral Muscular Dystrophy Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Fulcrum Therapeutics, Dyne Therapeutics, GSK, Roche, Facio Therapies, Myocea, Avidity Bios

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Facioscapulohumeral Muscular Dystrophy pipeline constitutes 10+ key companies continuously working towards developing 10+ Facioscapulohumeral Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Facioscapulohumeral Muscular Dystrophy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Facioscapulohumeral Muscular Dystrophy Market.

The Facioscapulohumeral Muscular Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Facioscapulohumeral Muscular Dystrophy Pipeline Report: https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Facioscapulohumeral Muscular Dystrophy treatment therapies with a considerable amount of success over the years.
• Facioscapulohumeral Muscular Dystrophy companies working in the treatment market are Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics, and others, are developing therapies for the Facioscapulohumeral Muscular Dystrophy treatment
• Emerging Facioscapulohumeral Muscular Dystrophy therapies in the different phases of clinical trials are- DYNE-301, MC-DX4, AOC 1020, ATYR 1940, Losmapimod, and others are expected to have a significant impact on the Facioscapulohumeral Muscular Dystrophy market in the coming years.
• In February 2023, Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical firm dedicated to introducing an innovative class of RNA therapies named Antibody Oligonucleotide Conjugates (AOCs™), recently disclosed that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to AOC 1020 intended for the treatment of facioscapulohumeral muscular dystrophy (FSHD). FSHD represents a severe, uncommon hereditary ailment characterized by persistent muscle weakening, leading to substantial pain, fatigue, and enduring disability over an individual's lifetime.
• In June 2022, Fulcrum Therapeutics initiated a multinational trial, employing a randomized, double-blind, and placebo-controlled design to assess the effectiveness and safety of losmapimod for treating FSHD. In this trial, patients will be randomly assigned in a 1:1 ratio to receive either losmapimod, administered orally as a 15 mg tablet twice daily, or a placebo, over a 48-week treatment duration. The study's primary endpoint will measure the absolute change from the baseline in Reachable Workspace (RWS). Secondary endpoints will encompass evaluations of muscle fat infiltration (MFI), Patient Global Impression of Change (PGIC), and Quality of Life in Neurological Disorders related to upper extremity (Neuro QoL UE). Additionally, the REACH study will include patient-centered assessments focusing on healthcare utilization.

Facioscapulohumeral Muscular Dystrophy Overview
Facioscapulohumeral Muscular Dystrophy (FSHD) is a neuromuscular disorder characterized by progressive muscle weakness and wasting. It primarily affects the muscles of the face (facio), shoulders (scapulo), and upper arms (humeral), although it can also involve muscles in other parts of the body.

Get a Free Sample PDF Report to know more about Facioscapulohumeral Muscular Dystrophy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Facioscapulohumeral Muscular Dystrophy Drugs Under Different Phases of Clinical Development Include:
• DYNE-301: Dyne Therapeutics
• MC-DX4: miRecule
• AOC 1020: Avidity Biosciences
• ATYR 1940: aTyr Pharma
• Losmapimod: Fulcrum Therapeutics

Facioscapulohumeral Muscular Dystrophy Route of Administration
Facioscapulohumeral Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Facioscapulohumeral Muscular Dystrophy Molecule Type
Facioscapulohumeral Muscular Dystrophy Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Facioscapulohumeral Muscular Dystrophy Pipeline Therapeutics Assessment
• Facioscapulohumeral Muscular Dystrophy Assessment by Product Type
• Facioscapulohumeral Muscular Dystrophy By Stage and Product Type
• Facioscapulohumeral Muscular Dystrophy Assessment by Route of Administration
• Facioscapulohumeral Muscular Dystrophy By Stage and Route of Administration
• Facioscapulohumeral Muscular Dystrophy Assessment by Molecule Type
• Facioscapulohumeral Muscular Dystrophy by Stage and Molecule Type

DelveInsight's Facioscapulohumeral Muscular Dystrophy Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Facioscapulohumeral Muscular Dystrophy product details are provided in the report. Download the Facioscapulohumeral Muscular Dystrophy pipeline report to learn more about the emerging Facioscapulohumeral Muscular Dystrophy therapies at:
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Facioscapulohumeral Muscular Dystrophy Therapeutics Market include:
Key companies developing therapies for Facioscapulohumeral Muscular Dystrophy are - Fulcrum Therapeutics, Dyne Therapeutics, GSK, Roche, Facio Therapies, Myocea, Avidity Biosciences, and others.

Facioscapulohumeral Muscular Dystrophy Pipeline Analysis:
The Facioscapulohumeral Muscular Dystrophy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Facioscapulohumeral Muscular Dystrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Facioscapulohumeral Muscular Dystrophy Treatment.
• Facioscapulohumeral Muscular Dystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Facioscapulohumeral Muscular Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Facioscapulohumeral Muscular Dystrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Facioscapulohumeral Muscular Dystrophy drugs and therapies-
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Facioscapulohumeral Muscular Dystrophy Pipeline Market Drivers
• Advancement in medical technology, investigation into the molecular consequences of DUX4 expression, demand for effective treatment options and novel therapies are some of the important factors that are fueling the Facioscapulohumeral Muscular Dystrophy Market.

Facioscapulohumeral Muscular Dystrophy Pipeline Market Barriers
• However, lack of approved therapies, complications involved with facioscapulohumeral muscular dystrophy and other factors are creating obstacles in the Facioscapulohumeral Muscular Dystrophy Market growth.

Scope of Facioscapulohumeral Muscular Dystrophy Pipeline Drug Insight
• Coverage: Global
• Key Facioscapulohumeral Muscular Dystrophy Companies: Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics, and others
• Key Facioscapulohumeral Muscular Dystrophy Therapies: DYNE-301, MC-DX4, AOC 1020, ATYR 1940, Losmapimod, and others
• Facioscapulohumeral Muscular Dystrophy Therapeutic Assessment: Facioscapulohumeral Muscular Dystrophy current marketed and Facioscapulohumeral Muscular Dystrophy emerging therapies
• Facioscapulohumeral Muscular Dystrophy Market Dynamics: Facioscapulohumeral Muscular Dystrophy market drivers and Facioscapulohumeral Muscular Dystrophy market barriers

Request for Sample PDF Report for Facioscapulohumeral Muscular Dystrophy Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Facioscapulohumeral Muscular Dystrophy Report Introduction
2. Facioscapulohumeral Muscular Dystrophy Executive Summary
3. Facioscapulohumeral Muscular Dystrophy Overview
4. Facioscapulohumeral Muscular Dystrophy- Analytical Perspective In-depth Commercial Assessment
5. Facioscapulohumeral Muscular Dystrophy Pipeline Therapeutics
6. Facioscapulohumeral Muscular Dystrophy Late Stage Products (Phase II/III)
7. Facioscapulohumeral Muscular Dystrophy Mid Stage Products (Phase II)
8. Facioscapulohumeral Muscular Dystrophy Early Stage Products (Phase I)
9. Facioscapulohumeral Muscular Dystrophy Preclinical Stage Products
10. Facioscapulohumeral Muscular Dystrophy Therapeutics Assessment
11. Facioscapulohumeral Muscular Dystrophy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Facioscapulohumeral Muscular Dystrophy Key Companies
14. Facioscapulohumeral Muscular Dystrophy Key Products
15. Facioscapulohumeral Muscular Dystrophy Unmet Needs
16 . Facioscapulohumeral Muscular Dystrophy Market Drivers and Barriers
17. Facioscapulohumeral Muscular Dystrophy Future Perspectives and Conclusion
18. Facioscapulohumeral Muscular Dystrophy Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Facioscapulohumeral Muscular Dystrophy Market https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Facioscapulohumeral Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Facioscapulohumeral Muscular Dystrophy Epidemiology https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Facioscapulohumeral Muscular Dystrophy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Lung Transplant Rejection Market https://www.delveinsight.com/report-store/lung-transplant-rejection-market
DelveInsight's "Lung Transplant Rejection Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Lung Transplant Rejection, historical and forecasted epidemiology as well as the Lung Transplant Rejection market trends in the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.

CAR T-Cell Therapy for Multiple Myeloma Market
https://www.delveinsight.com/report-store/car-t-cell-therapy-for-multiple-myeloma-market
DelveInsight's "CAR-T Cell Therapy for Multiple Myeloma Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of multiple myeloma and various CAR-Ts used in multiple myeloma, and CAR-Ts historical and forecasted market trends in multiple myeloma in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Insulin Resistance Market
https://www.delveinsight.com/report-store/insulin-resistance-market
DelveInsight's "Insulin Resistance Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Insulin Resistance, historical and forecasted epidemiology as well as the Insulin Resistance market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Dyskinesia Market
https://www.delveinsight.com/report-store/dyskinesia-market
DelveInsight's "Dyskinesia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Dyskinesia, historical and forecasted epidemiology as well as the Dyskinesia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hemophilia Market
https://www.delveinsight.com/report-store/hemophilia-market
DelveInsight's "Hemophilia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hemophilia, historical and forecasted epidemiology as well as the Hemophilia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Paroxysmal Nocturnal Hemoglobinuria Market
https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-market
DelveInsight's 'Paroxysmal Nocturnal Hemoglobinuria Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of Paroxysmal Nocturnal Hemoglobinuria historical and forecasted epidemiology as well as the Paroxysmal Nocturnal Hemoglobinuria market trends in the United States, the EU4 (Germany, France, Italy, Spain), the UK and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.